Research

Hormonal

Central nervous system (CNS) activation of the Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) is required for the synergistic weight loss observed with dual GIPR/GLP-1R agonists.

If you are using a GLP-1 medication for weight loss or diabetes and struggle with side effects or plateauing results, newer dual-acting medications (targeting both GIP and GLP-1 receptors) may offer better weight loss with potentially fewer gastrointestinal side effects. This is because these drugs work on brain pathways that suppress appetite and may reduce the nausea often caused by older GLP-1-only drugs. Consult your doctor about whether a dual-agonist is appropriate for your metabolic health.

GoodSupportsHIGH confidence
activation of GIPR in certain areas of the brain that regulate energy balance is required for the synergistic weight loss of dual GIPR and GLP-1 receptor (GLP-1R) agonism.
Ricardo J. Samms et al. · Diabetes · 2021

Why this rating

Based on multiple preclinical models (knockouts, chemogenetics) and clinical trial data cited, though the exact neuronal circuits are still being mapped.

Source

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders

Ricardo J. Samms et al. · Diabetes · 2021

DOI 10.2337/dbi21-0002

narrative_reviewCited 44×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →